These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis. Baader M; Bretschneider T; Broermann A; Rippmann JF; Stierstorfer B; Kuttruff CA; Mark M Br J Pharmacol; 2018 Feb; 175(4):693-707. PubMed ID: 29197066 [TBL] [Abstract][Full Text] [Related]
16. [Clinical introduction of lysophosphatidic acid and autotaxin assays]. Yatomi Y Rinsho Byori; 2010 Jun; 58(6):631-5. PubMed ID: 20662276 [TBL] [Abstract][Full Text] [Related]
17. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. David M; Wannecq E; Descotes F; Jansen S; Deux B; Ribeiro J; Serre CM; Grès S; Bendriss-Vermare N; Bollen M; Saez S; Aoki J; Saulnier-Blache JS; Clézardin P; Peyruchaud O PLoS One; 2010 Mar; 5(3):e9741. PubMed ID: 20305819 [TBL] [Abstract][Full Text] [Related]